编者按：2026年欧洲肿瘤内科学会亚洲年会（ESMO ASIA 2026）将于12月4日-6日在新加坡举办，汇聚亚太及全球肿瘤临床专家、科研工作者、医药从业者，聚焦亚洲高发肿瘤，分享药物研发、精准肿瘤学领域前沿成果，引领亚太地区肿瘤诊疗的创新发展。目前，ESMO官网已公布本届大会口头报告、快速口头报告及壁报摘要信息，中国研究者贡献了多项药物研发与精准治疗方向的重磅研究成果。基于现有公开资料，《肿瘤瞭望》特别整理中国学者在治疗发展与精准治疗专场带来的最新学术进展，供大家提前参考了解。内容若有疏漏谬误，敬请留言指正。
Proffered Paper session: Developmental therapeutics and precision medicine
时间：2026年12月4日10:45 - 12:15
地点：Hall 402
摘要号：237O
英文标题：First-in-human study of VBC103, a bispecific antibody drug conjugate (ADC) targeting Nectin-4 and TROP2 as monotherapy in participants with advanced solid tumors
中文标题：VBC103（靶向Nectin-4与TROP2的双特异性抗体药物偶联物）用于晚期实体瘤受试者单药治疗的首个人体研究
讲者：张剑（复旦大学附属肿瘤医院）
摘要号：238O
英文标题：Izalontamab Brengitecan (iza-bren) in Patients with Pretreated Advanced Hepatocellular Carcinoma (HCC): Results from Two Phase I/II Studies
中文标题：Izalontamab Brengitecan（iza-bren）用于经治晚期肝细胞癌（HCC）患者：两项Ⅰ/Ⅱ期研究结果
讲者：周俭（复旦大学附属中山医院）
摘要号：239O
英文标题：Efficacy and safety of Trastuzumab Brengitecan (T-Bren) in patients with HER2-expressing locally advanced or metastatic colorectal cancer: Results from three phase I/II studies
中文标题：Trastuzumab Brengitecan（T-Bren）用于HER2表达的局部晚期或转移性结直肠癌患者的疗效与安全性：三项Ⅰ/Ⅱ期研究结果
讲者：张雯（中国医学科学院肿瘤医院）
摘要号：LBA2
英文标题：First-in-human (FIH) phase 1 study of the oral pan-RAS inhibitor HRS-2329 in advanced RAS-mutant solid tumors
中文标题：口服泛RAS抑制剂HRS-2329用于晚期RAS突变实体瘤的首个人体（FIH）I期研究
讲者：余俊（天津医科大学肿瘤医院）
Rapid Oral session: Developmental therapeutics and precision medicine
时间：2026年12月6日10:45 - 12:15
地点：Hall 407
摘要号：241RO
英文标题：Phase I/II Study of CVL006, A Novel Anti-PD-L1/VEGF Bispecific Antibody in Combination with Chemotherapy, ADCs Targeted Therapy for Patients with Advanced Solid Tumors
中文标题：新型抗PD-L1/VEGF双特异性抗体CVL006联合化疗、抗体药物偶联物及靶向治疗用于晚期实体瘤患者的Ⅰ/Ⅱ期研究
讲者：张力（中山大学肿瘤防治中心）
摘要号：243RO
英文标题：Phase II Study of Izalontamab Brengitecan (iza-bren) Combined with Toripalimab in Patients with Recurrent or Metastatic (R/M) Nasopharyngeal Cancer (NPC)
中文标题：Izalontamab Brengitecan（iza-bren）联合特瑞普利单抗治疗复发或转移性（R/M）鼻咽癌（NPC）患者的Ⅱ期研究
讲者：Yuanyuan Zhao (Guangzhou, CN)
摘要号：244RO
英文标题：Efficacy and safety of Trastuzumab Brengitecan (T-Bren) in patients with HER2-expressing locally advanced or metastatic urothelial carcinoma: Results from a phase Ib/II study
中文标题：Trastuzumab Brengitecan（T-Bren）用于HER2表达的局部晚期或转移性尿路上皮癌患者的疗效与安全性：一项Ⅰb/Ⅱ期研究结果
讲者：周爱萍（中国医学科学院肿瘤医院）
摘要号：245RO
英文标题：Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts) in China with HER2 IHC 3+ solid tumors: DESTINY-PanTumor03 (DP-03) Part 1 final analysis
中文标题：德曲妥珠单抗（T-DXd）用于中国经治HER2免疫组化3+实体瘤患者：DESTINY-PanTumor03（DP-03）第1部分最终分析
讲者：吴小华（复旦大学附属肿瘤医院）
摘要号：246RO
英文标题：JSKN016, a First-in-Class TROP2/HER3 Bispecific Antibody–Drug Conjugate (ADC), in Pretreated Non-Small Cell Lung Cancer (NSCLC) with Rare/Uncommon Driver Genomic Alterations (DGAs)
中文标题：JSKN016，一款首创型TROP2/HER3双特异性抗体药物偶联物（ADC），用于携带罕见/非典型驱动基因变异（DGAs）的经治非小细胞肺癌（NSCLC）
讲者：洪少东（中山大学肿瘤防治中心）
摘要号：248RO
英文标题：Phase I/II safety and efficacy of WSD0922-FU in non-small cell lung cancer patients harboring EGFR C797S mutations
中文标题：WSD0922-FU用于携带EGFRC797S突变的非小细胞肺癌患者的Ⅰ/Ⅱ期安全性与疗效研究
讲者：周彩存（同济大学附属东方医院）
Posters and ePosters
Developmental therapeutics
摘要号：292eP
英文标题：Colorectal cancer-derived extracellular vesicles induce coronary microvascular endothelial dysfunction through metabolic reprogramming
中文标题：结直肠癌来源的细胞外囊泡通过代谢重编程诱导冠状动脉微血管内皮功能障碍
讲者：Zhongwei Liu (Xi'an, CN)
摘要号：284eP
英文标题：Proteolysis-targeting chimera (PROTAC) targeting Bruton tyrosine kinase (BTK) degradation in mantle cell lymphoma
中文标题：靶向布鲁顿酪氨酸激酶（BTK）降解的蛋白水解靶向嵌合体（PROTAC）在套细胞淋巴瘤中的研究
讲者：Junlei Jia (Tianjin, CN)
摘要号：283eP
英文标题：Resibufogenin restores necroptotic vulnerability in acute myeloid leukemia through HOIP inhibition
中文标题：脂蟾毒配基通过抑制 HOIP 恢复急性髓系白血病的坏死性凋亡易感性
讲者：Miaomiao Jia (Zhengzhou, CN)
摘要号：277P
英文标题：Targeting the preserved CD2 axis improves the depth and durability of DLL3-directed T-cell engager therapy in small cell lung cancer
中文标题：靶向保留的CD2轴可提升小细胞肺癌中DLL3靶向T细胞衔接器治疗的缓解深度与持久性
讲者：Qian Chu (Wuhan, CN)
摘要号：276P
英文标题：Autophagic STING Degradation Drives Impaired Chemotherapy-Induced ICD in LKB1-mutant Lung Adenocarcinoma
中文标题：自噬介导的STING降解导致LKB1突变肺腺癌化疗诱导的免疫原性细胞死亡受损
讲者：Nan Jiang (Hangzhou, CN)
摘要号：273P
英文标题：Mechanistic investigation of PIM1-Mediated inhibition of CD8⁺ T cell function and promotion of tumor immune escape
中文标题：PIM1介导抑制CD8⁺T细胞功能并促进肿瘤免疫逃逸的机制研究
讲者：Ning Zhang (Tianjin, CN)
摘要号：272P
英文标题：Development of a novel trifunctional IL2v-NK cell engager platform for cancer immunotherapy
中文标题：新型三功能IL2v-NK细胞衔接平台的研发，用于肿瘤免疫治疗
讲者：Yangyang Li (Hefei, CN)
摘要号：268P
英文标题：Orelabrutinib, Lenalidomide, and Rituximab as Frontline Therapy for Mantle Cell Lymphoma: Results of the Phase II POLARIS Study
中文标题：奥布替尼、来那度胺联合利妥昔单抗一线治疗套细胞淋巴瘤：Ⅱ期POLARIS研究结果
讲者：宋拯（天津医科大学肿瘤医院）
摘要号：264P
英文标题：First-in-human phase I/II study of HRS-6213, a novel 18F-labeled FAP-targeted PET tracer, for imaging solid tumors
中文标题：新型18F标记FAP靶向PET示踪剂HRS-6213用于实体瘤显像的首个人体Ⅰ/Ⅱ期研究
讲者：郝继辉（天津医科大学肿瘤医院）
摘要号：263P
英文标题：Efficacy, Safety, and Tolerability of HS-10516, a Selective HIF-2α Inhibitor, in Chinese Patients with VHL Disease-Associated Tumors: A Phase 1 Study
中文标题：选择性HIF-2α抑制剂HS-10516用于中国VHL病相关肿瘤患者的疗效、安全性与耐受性：一项I期研究
讲者：Jianhui Qiu (Beijing, CN)
摘要号：261P
英文标题：Pimicotinib (pimi) in patients (pts) with tenosynovial giant cell tumor (TGCT) from China: 1-year safety results from the phase 3 MANEUVER trial
中文标题：匹米替尼（pimi）用于中国腱鞘巨细胞瘤（TGCT）患者：Ⅲ期MANEUVER研究1年安全性结果
讲者：牛晓辉（首都医科大学附属北京积水潭医院）
摘要号：260P
英文标题：Phase 1 Study of Bifunctional Anti-PD-1/IL-2 Fusion Protein AWT020 in Patients With Advanced Tumors
中文标题：双功能抗PD-1/IL-2融合蛋白AWT020用于晚期肿瘤患者的I期研究
讲者：陆舜 （上海市胸科医院）
摘要号：259P
英文标题：Intratumoral Flt3L mRNA Lipid Nanoparticles Reprogram Dendritic Cells and Enhance Antitumor Immunity
中文标题：瘤内注射Flt3L mRNA脂质纳米颗粒可重编程树突状细胞并增强抗肿瘤免疫
讲者：Yao Chen (Hangzhou, CN)
摘要号：258P
英文标题：SIM01 Potentiates Anti–PD-L1 Therapy Through Microbiome and Immune Modulation in NSCLC
中文标题：SIM01通过微生物组与免疫调节增强非小细胞肺癌抗PD-L1治疗的疗效
讲者：Tsz Tung Kwong (Hong Kong, HK)
摘要号：257P
英文标题：HCB101-based CD47–SIRPα blockade in PD-1–naïve R/M HNSCC and 2L CRC
中文标题：基于HCB101的CD47-SIRPα阻断治疗用于PD-1初治复发/转移性头颈部鳞状细胞癌以及二线结直肠癌
讲者：Peter Mu-Hsin Chang (Taipei City, TW)
摘要号：256P
英文标题：HCB301, a trispecific SIRPα–PD-L1–TGFβ fusion protein, in patients with advanced malignancies
中文标题：三特异性SIRPα-PD-L1-TGFβ融合蛋白HCB301用于晚期恶性肿瘤患者的研究
讲者：Ji Zhu (Hangzhou, CN)
摘要号：255P
英文标题：An allogeneic NKG2D-NKR-NK cell therapy with long persistence: Phase 1 interim results
中文标题：具有长期存续性的异体NKG2D-NKR-NK细胞治疗：I期中期研究结果
讲者：Dan Liu (Beijing, CN)
摘要号：254P
英文标题：GC101 TIL in Patients with Advanced Mucosal Melanoma after anti-PD-1 Failure: A Subgroup Analysis of a Randomized Phase II Trial
中文标题：GC101肿瘤浸润淋巴细胞用于抗PD-1治疗失败的晚期黏膜黑色素瘤患者：一项随机Ⅱ期研究的亚组分析
讲者：毛丽丽（北京大学肿瘤医院）
摘要号：253P
英文标题：Clinical Efficacy and Safety of BM201 Intra-tumoral Injection and Radiotherapy in Advanced Solid Tumors: Results from the Phase I/IIT Study
中文标题：BM201瘤内注射联合放疗用于晚期实体瘤的临床疗效与安全性：I期研究者发起临床试验（IIT）研究结果
讲者：李茹恬（南京大学医学院附属鼓楼医院）
摘要号：251P
英文标题：Izalontamab Brengitecan (iza-bren) in Patients with Advanced Cervical Cancer (CC) or Endometrial Cancer (EC) Progressed on Platinum-Based Chemotherapy (PBC): Results from Two Phase II Studies
中文标题：Izalontamab Brengitecan（iza-bren）用于铂类化疗进展的晚期宫颈癌（CC）或子宫内膜癌（EC）患者：两项Ⅱ期研究结果
讲者：Rujiao Liu (Shanghai, CN)
摘要号：250P
英文标题：Efficacy and safety of Trastuzumab Brengitecan (T-Bren) in patients with HER2-expressing locally advanced or metastatic biliary tract cancer: Results from two phase I/II studies
中文标题：Trastuzumab Brengitecan（T-Bren）用于HER2表达局部晚期或转移性胆道肿瘤患者的疗效与安全性：两项Ⅰ/Ⅱ期研究结果
讲者：周爱萍（中国医学科学院肿瘤医院）
摘要号：249P
英文标题：Phase II Study of First Line Izalontamab Brengitecan Combined with Sintilimab in Patients with HER2-Negative Gastric or Gastroesophageal Junction Cancer (GC/GEJ)
中文标题：Izalontamab Brengitecan联合信迪利单抗一线治疗HER2阴性胃癌或胃食管结合部癌（GC/GEJ）患者的Ⅱ期研究
讲者：Wei He (Zhengzhou, CN)
Precision medicine
摘要号：YO19
英文标题：Durable response to trastuzumab deruxtecan (T-DXd) in platinum resistant primary peritoneal carcinoma with sequencing detected ERBB2 amplification: a case report
中文标题：测序检出ERBB2扩增的铂耐药原发性腹膜癌患者经德曲妥珠单抗（T-DXd）治疗获得持久缓解：一例病例报告
讲者：Chiu Hang Mok (Kowloon, HK)
摘要号：YO20
英文标题：Long-Term Survival in PIK3CA-Mutated Metastatic Myxoid Liposarcoma Treated with Combined PI3K-Targeted Chemotherapy and Brachytherapy: A Case Report
中文标题：PIK3CA突变型转移性黏液样脂肪肉瘤接受PI3K靶向化疗联合近距离放疗后的长期生存：一例病例报告
讲者：Yuanyuan Gu (Beijing, CN)
摘要号：737eTiP
英文标题：Luvometinib Switch Therapy in Pediatric Patients with NF1-Associated Plexiform Neurofibromas: A Single-Center, Prospective Real-World Study
中文标题：Luvometinib转换治疗用于伴NF1的丛状神经纤维瘤儿童患者：一项单中心、前瞻性真实世界研究
讲者：顾松（上海儿童医学中心）
摘要号：736eTiP
英文标题：Longitudinal Proteomic Profiling in Patients with NF1-Related Plexiform Neurofibromas Treated with Luvometinib: A Prospective Observational Study
中文标题：Luvometinib治疗的NF1相关丛状神经纤维瘤患者纵向蛋白质组学图谱分析：一项前瞻性观察性研究
讲者：Zhen Zhang (Jinan, CN)
摘要号：732eP
英文标题：EUD Spatial Topological Optimisation Coupled with Multimodal Imaging Features for Assessing Tumour Imaging Response after Spatially Fractionated Radiotherapy
中文标题：结合多模态影像特征的 EUD 空间拓扑优化用于评估空间分割放疗后的肿瘤影像缓解
讲者：Yi Peng (Chengdu, CN)
摘要号：726eP
英文标题：Preclinical evaluation and target characterization of cyclic peptide C5 in triple-negative breast cancer
中文标题：环肽C5在三阴性乳腺癌中的临床前评价及靶点特征研究
讲者：Qichen Dai (Beijing, CN)
摘要号：724eP
英文标题：Integrating Multi‑layer Transcriptomics to Decipher the Characteristics of Key Cell Subpopulations in Mitoxyperilysis and Construct a Prognostic Model in Gastric Cancer
中文标题：整合多层转录组学解析丝裂过氧化作用中关键细胞亚群特征并构建胃癌预后模型
讲者：Yu Zhou (Fuzhou, CN)
摘要号：720eP
英文标题：From epithelial cell states to patient risk: single-cell-guided molecular stratification in lung adenocarcinoma
中文标题：从上皮细胞状态到患者风险：肺腺癌中单细胞技术指导下的分子分层研究
讲者：Ruizhe Huang (Shanghai, CN)
摘要号：718eP
英文标题：Advancing Early-Stage Tumor Capture: OncoSeek Elevates Sensitivity in Economical Multi-Cancer Blood Testing
中文标题：推进早期肿瘤捕获：OncoSeek提升经济型多癌种血液检测的灵敏度
讲者：Yong Shen (Zhengzhou, CN)
摘要号：711eP
英文标题：Multi-omics Integration Reveals a Novel Synergistic Anti-Breast Cancer Mechanism of Trastuzumab Deruxtecan Combined with Lapatinib
中文标题：多组学整合揭示德曲妥珠单抗联合拉帕替尼全新的协同抗乳腺癌机制
讲者：Yijun Li (Xi'an, CN)
摘要号：708TiP
英文标题：A Phase III Study Comparing Luvometinib to Standard First-Line Systemic Therapy in Children with Newly Diagnosed Langerhans Cell Histiocytosis
中文标题：一项比较Luvometinib与标准一线系统治疗用于初诊朗格汉斯细胞组织细胞增生症患儿的Ⅲ期研究
讲者：Yanlai Tang (Guangzhou, CN)
摘要号：707TiP
英文标题：A phase II study of sacituzumab tirumotecan combined with tagitanlimab as first-line treatment for patients with KRAS-mutant advanced non-small cell lung cancer
中文标题：芦康沙妥珠单抗联合塔戈利单抗一线治疗KRAS突变晚期非小细胞肺癌患者的Ⅱ期研究
讲者：Fangqi Li (Shanghai, CN)
摘要号：705P
英文标题：Patient-derived 3D-bioprinted pan-digestive tumor models for precision oncology: a cross-tumor translational study
中文标题：用于精准肿瘤学的患者来源3D生物打印泛消化道肿瘤模型：一项跨瘤种转化研究
讲者：Liwei Du (Beijing, CN)
摘要号：698P
英文标题：Longitudinal CT-only radiomics for immunotherapy response in advanced EGFR-wild type non-small cell lung cancer
中文标题：基于纵向单纯CT影像组学预测晚期EGFR野生型非小细胞肺癌免疫治疗疗效
讲者：Xiaomin Niu (Shanghai, CN)
摘要号：694P
英文标题：Pan-cancer immune context of antibody–drug conjugate (ADC) efficacy and adverse-event-specific pharmacovigilance
中文标题：泛癌层面抗体药物偶联物（ADC）疗效的免疫背景及不良反应特异性药物警戒研究
讲者：Jingsong Cheng (Guangzhou, CN)
摘要号：693P
英文标题：Immunometabolic Features and Potential Clinical Value of Ferroptosis–Nucleic Acid Metabolism Coupling in Triple-Negative Breast Cancer
中文标题：三阴性乳腺癌中铁死亡-核酸代谢偶联的免疫代谢特征及其潜在临床价值
讲者：He Hao (Taiyuan, CN)
摘要号：687P
英文标题：Real-world utilization of tissue-free minimal residual disease (MRD) testing in patients with solid tumors from Asia and the Middle East (AMEA)
中文标题：亚洲及中东（AMEA）地区实体瘤患者无组织微小残留病灶（MRD）检测的真实世界应用研究
讲者：Yao-Yu Hsieh (New Taipei City, TW)
摘要号：685P
英文标题：Spatially resolved neutrophil-macrophage-tumour crosstalk in the epithelial-mesenchymal transition niche of lung adenocarcinoma
中文标题：肺腺癌上皮间质转化微环境中空间分辨的中性粒细胞 - 巨噬细胞 - 肿瘤细胞交互作用
讲者：Ruizhe Huang (Shanghai, CN)
摘要号：678P
英文标题：A multimodal causal-temporal framework linking anti-PD-1 response prediction to therapeutic intervention in NSCLC
中文标题：用于非小细胞肺癌抗PD-1疗效预测与治疗干预关联的多模态因果时序框架
讲者：Bowen Chu (Nanjing, CN)
摘要号：675P
英文标题：Retrospective Real-World Genomic Landscape of BRCA1/2 and Homologous Recombination Repair (HRR) Gene Alterations Across Breast, Ovarian, Pancreatic, and Prostate Cancers in a Taiwanese Cohort
中文标题：中国台湾队列中乳腺癌、卵巢癌、胰腺癌和前列腺癌BRCA1/2及同源重组修复（HRR）基因变异的回顾性真实世界基因组图谱研究
讲者：Yeh-Han Wang (New Taipei City, TW)
摘要号：670P
英文标题：Performance of Cell-Free DNA (cfDNA) Methylation-Based Multi-Cancer Early Detection (MCED) Assay in Heavy Smokers for Tobacco-Associated Malignancies
中文标题：基于游离DNA（cfDNA）甲基化的多癌种早期检测（MCED）试剂盒在重度吸烟者中筛查烟草相关恶性肿瘤的效能研究
讲者：Xiangnan Li (Zhengzhou, CN)
摘要号：667P
英文标题：Validation of a Cell-Free DNA (cfDNA) Methylation-Based Multi-Cancer Early Detection (MCED) Assay Among Patients with Diabetes Mellitus
中文标题：基于游离DNA（cfDNA）甲基化的多癌种早期检测（MCED）试剂盒在糖尿病患者中的验证研究
讲者：Jiandong Tai (Changchun, CN)
摘要号：665P
英文标题：KRAS Mutational Landscape in Advanced Cancers Across Asia and the Middle East: A Real-World Circulating Tumor DNA Study
中文标题：亚洲及中东地区晚期癌症KRAS突变图谱：一项基于循环肿瘤DNA的真实世界研究
讲者：Ming-Huang Chen (Taipei City, TW)
摘要号：663P
英文标题：Zurletrectinib in NTRK Fusion-Positive Solid Tumors: an Integrated Efficacy and Safety Analysis of Three Open-Label Single-Arm Clinical Trials
中文标题：Zurletrectinib用于NTRK融合阳性实体瘤：三项开放标签单臂临床试验的合并疗效与安全性分析
讲者：Danyun Ruan (Guangzhou, CN)